Democrat Congressman from Oregon, Earl Blumenauer, has often been called the “Top Legal Pot Advocate” in the House of Representatives. Known for two decades of medical cannabis advocacy, Blumenauer recently co-authored a bipartisan bill with Republican Congressman Andy Harris (MD) that would cut through the bureaucratic red tape hampering marijuana research at the federal level.
The current head of the Department of Justice has made no secret of his feelings about cannabis. From calling medical marijuana “a joke” to making comments such as “good people don’t smoke marijuana,” it’s clear that the Attorney General is opposed to cannabis in all forms. That includes supporting research that could reveal major health
California was the first state to legalize cannabis for medical purposes. Now, a new joint resolution by the Golden State’s legislature aims to remove federal barriers to widespread access to cannabis for research and medical purposes. In a resolution overwhelmingly approved on September 14, 2017, California lawmakers voted to urge Congress to remove marijuana from
Recent studies have shown that people in the U.S. are increasingly turning to medical marijuana to treat a variety of health issues, and that could spell big trouble for Big Pharma. Twenty-eight states and Washington D.C. have now passed medical marijuana legislation. Across these legal markets, prescriptions for pharmaceuticals have been consistently declining in categories
In a potentially game-changing development for the medical marijuana community, Republican Senator Orrin Hatch, who has represented Utah since 1977 and is well known for his hardline conservatism, recently introduced a bill to the Senate that would streamline medical research on cannabis at the federal level. The Marijuana Effective Drug Study Act of 2017, or